Geneva Capital Management LLC Sells 41,590 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Geneva Capital Management LLC trimmed its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 938,944 shares of the company’s stock after selling 41,590 shares during the quarter. Geneva Capital Management LLC owned 2.06% of Omnicell worth $35,332,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Covestor Ltd boosted its holdings in Omnicell by 65.6% in the third quarter. Covestor Ltd now owns 1,355 shares of the company’s stock worth $61,000 after acquiring an additional 537 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Omnicell during the third quarter valued at $62,000. Neo Ivy Capital Management bought a new position in shares of Omnicell during the third quarter valued at $78,000. Fifth Third Bancorp lifted its holdings in shares of Omnicell by 143.2% during the third quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock valued at $100,000 after purchasing an additional 1,313 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Omnicell by 110.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,392 shares of the company’s stock valued at $153,000 after purchasing an additional 1,777 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on OMCL. Benchmark reaffirmed a “buy” rating and set a $38.00 price target on shares of Omnicell in a report on Tuesday, April 30th. Wells Fargo & Company lowered their price target on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

Omnicell stock traded up $0.29 during mid-day trading on Thursday, reaching $30.25. 679,330 shares of the stock traded hands, compared to its average volume of 537,458. The stock has a market capitalization of $1.39 billion, a PE ratio of -65.76, a price-to-earnings-growth ratio of 237.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The business’s 50-day moving average is $27.99 and its 200-day moving average is $31.50. Omnicell, Inc. has a 12-month low of $25.69 and a 12-month high of $77.14.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The firm had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. As a group, sell-side analysts predict that Omnicell, Inc. will post 0.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.